[Treatment of metastatic prostatic cancer with monthly injections of leuprolide acetate depot]. 1994

J F Jiménez Cruz, and C D Vera Donoso, and I Iborra, and E Solsona, and E Forner, and H Villavicencio, and C Díaz, and C González, and L Rioja, and C Pertusa
Instituto Valenciano de Oncología, Hospital La Fe, Valencia.

Seventy-two patients were admitted in a multicentre trial with the purpose of assessing the clinical efficacy and safety of the hormonal control and tolerance of leuprolide acetate in a once-a-month depot injection formulation for the treatment of disseminated prostate cancer. During a 1-year follow-up, there were ten withdrawals for different reasons. At baseline and at 6 months of treatment the following parameters were evaluated: clinical examination, routine blood analysis, PAP, PSA, LH and testosterone, as well as bone scan. LH and testosterone determinations were repeated at 2, 4, 8, 12, 16, 20 and 24 weeks. Testosterone reached castration levels within the second week and was maintained until the end of the study. In agreement with the NPCP criteria, 65 patients were assessed as: complete response 3%, partial response 40%, disease stabilization 36%, and progression 21%. In summary, a once-a-month injection of leuprolide acetate offers a safe and effective alternative to surgical castration.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

J F Jiménez Cruz, and C D Vera Donoso, and I Iborra, and E Solsona, and E Forner, and H Villavicencio, and C Díaz, and C González, and L Rioja, and C Pertusa
January 1988, Acta oncologica (Stockholm, Sweden),
J F Jiménez Cruz, and C D Vera Donoso, and I Iborra, and E Solsona, and E Forner, and H Villavicencio, and C Díaz, and C González, and L Rioja, and C Pertusa
February 1993, Fertility and sterility,
J F Jiménez Cruz, and C D Vera Donoso, and I Iborra, and E Solsona, and E Forner, and H Villavicencio, and C Díaz, and C González, and L Rioja, and C Pertusa
September 1989, The Journal of clinical endocrinology and metabolism,
J F Jiménez Cruz, and C D Vera Donoso, and I Iborra, and E Solsona, and E Forner, and H Villavicencio, and C Díaz, and C González, and L Rioja, and C Pertusa
January 1997, Oncology reports,
J F Jiménez Cruz, and C D Vera Donoso, and I Iborra, and E Solsona, and E Forner, and H Villavicencio, and C Díaz, and C González, and L Rioja, and C Pertusa
March 2007, Clinical genitourinary cancer,
J F Jiménez Cruz, and C D Vera Donoso, and I Iborra, and E Solsona, and E Forner, and H Villavicencio, and C Díaz, and C González, and L Rioja, and C Pertusa
January 1987, Journal of andrology,
J F Jiménez Cruz, and C D Vera Donoso, and I Iborra, and E Solsona, and E Forner, and H Villavicencio, and C Díaz, and C González, and L Rioja, and C Pertusa
February 1994, The Annals of pharmacotherapy,
J F Jiménez Cruz, and C D Vera Donoso, and I Iborra, and E Solsona, and E Forner, and H Villavicencio, and C Díaz, and C González, and L Rioja, and C Pertusa
October 1987, Lakartidningen,
J F Jiménez Cruz, and C D Vera Donoso, and I Iborra, and E Solsona, and E Forner, and H Villavicencio, and C Díaz, and C González, and L Rioja, and C Pertusa
July 1991, The Journal of clinical endocrinology and metabolism,
J F Jiménez Cruz, and C D Vera Donoso, and I Iborra, and E Solsona, and E Forner, and H Villavicencio, and C Díaz, and C González, and L Rioja, and C Pertusa
July 1989, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!